Wells Fargo & Company Vaxcyte, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PCVX
# of Institutions
286Shares Held
110MCall Options Held
248KPut Options Held
109K-
Black Rock Inc. New York, NY9.94MShares$1.11 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.8MShares$1.09 Billion0.01% of portfolio
-
Janus Henderson Group PLC London, X08.87MShares$989 Million0.37% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.2MShares$915 Million9.34% of portfolio
-
Wellington Management Group LLP Boston, MA4.59MShares$512 Million0.06% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $6.62B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...